10-Q: BioCardia Q3 2025: Clinical Progress Amidst Funding Challenges

BioCardia reports significant clinical trial advancements for its cell therapies and delivery systems, alongside ongoing capital raises and a going concern warning.

Summary

• Net loss for the three months ended September 30, 2025, was $1.483 million, an improvement from $1.737 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $6.244 million, compared to $5.650 million for the same period in 2024.
• Cash and cash equivalents increased to $5.287 million as of September 30, 2025, from $2.371 million at December 31, 2024.
• Research and development expenses increased to $3.834 million for the nine months ended September 30, 2025, from $2.972 million in the prior year, primarily due to CardiAMP Heart Failure Trial closeout and CardiAMP Heart Failure II Trial enrollment.
• Selling, general and administrative expenses decreased to $2.431 million for the nine months ended September 30, 2025, from $2.766 million in the prior year, mainly due to lower professional service fees and share-based compensation.
• The company raised approximately $7.856 million in net cash from financing activities during the nine months ended September 30, 2025, primarily through sales of common stock and warrants.
• Two-year results from the CardiAMP Heart Failure Trial showed a statistically significant composite endpoint in patients with elevated NTproBNP, leading to a positive preliminary consultation with Japan's PMDA.
• Patient randomization has commenced in the CardiAMP HF II Phase 3 trial, and the open-label roll-in cohort for the CardiAMP Chronic Myocardial Ischemia trial showed an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes.
• The CardiALLO allogeneic MSC Phase 1/2 trial's low dose cohort completed with no treatment-emergent adverse events, and the Data Safety Monitoring Board recommended proceeding.
• The company's cash and cash equivalents are not sufficient to fund planned expenditures beyond the second quarter of 2026, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: While there are positive clinical trial results and progress, the severe liquidity issues, explicit going concern warning, and significant capital raise challenges (including the Form S-3 limitation) overshadow the operational advancements. The company is in a precarious financial position requiring immediate and substantial funding.

Positives

• Net loss decreased for the three months ended September 30, 2025, to $1.483 million from $1.737 million in the prior year period.
• Net loss per share significantly improved for both the three-month ($0.24 vs $0.61) and nine-month ($1.17 vs $2.65) periods, primarily due to an increased weighted-average share count.
• Cash and cash equivalents increased to $5.287 million as of September 30, 2025, from $2.371 million at December 31, 2024.
• Positive two-year results from the CardiAMP Heart Failure Trial demonstrated reduction in all-cause death, reduced major adverse cardiac events, and improved quality of life, with a statistically significant composite endpoint in patients having elevated NTproBNP.
• Received positive preliminary clinical consultation with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on CardiAMP Heart Failure Trial data, potentially enabling submission for market entry approval in Japan.
• Patient randomization has commenced in the CardiAMP HF II Phase 3 trial for ischemic heart failure with reduced ejection fraction (HFrEF).
• The open-label roll-in cohort of the CardiAMP Chronic Myocardial Ischemia trial showed promising results, with an average 107-second increase in exercise tolerance and an 82% average reduction in angina episodes at the six-month follow-up.
• The low dose cohort of the CardiALLO allogeneic mesenchymal stem cell (MSC) Phase 1/2 trial for ischemic HFrEF has been completed with no treatment-emergent adverse events, and the Data Safety Monitoring Board recommended proceeding.
• Received FDA market clearance for an 8 French equivalent Morph DNA steerable introducer (AVANCE) for transseptal cardiac procedures.
• Medicare reimbursement code C9782, at $17,500, helps offset the costs of both the CardiAMP Heart Failure and Chronic Myocardial Ischemia trials.

Negatives

• The company has incurred net losses and negative cash flows from operations since its inception, with an accumulated deficit of approximately $166.4 million as of September 30, 2025.
• Cash and cash equivalents of $5.287 million as of September 30, 2025, are not sufficient to fund planned expenditures beyond the second quarter of 2026, raising substantial doubt about the company's ability to continue as a going concern.
• Net loss for the nine months ended September 30, 2025, worsened to $6.244 million from $5.650 million in the prior year period.
• Collaboration agreement revenue was $0 for both the three and nine months ended September 30, 2025, a decrease from $58,000 in the nine months ended September 30, 2024.
• Research and development expenses increased for the nine-month period, indicating a higher burn rate for advancing clinical trials.
• Significant dilution occurred due to multiple equity and warrant offerings, increasing common shares outstanding from 4,600,910 at December 31, 2024, to 10,608,734 at September 30, 2025.
• The company faces a temporary limitation on utilizing Form S-3 without an SEC waiver, which will materially and adversely impact its ability to raise capital efficiently and use its at-the-market program.

Risks

• There is substantial doubt about the company's ability to continue as a going concern beyond the second quarter of 2026 due to ongoing net losses and negative cash flows, necessitating additional capital.
• Inability to raise adequate additional capital could force the company to reduce operating expenses, delay or reduce product development programs, relinquish rights to technologies, or cease operations.
• Failure to satisfy Nasdaq continued listing requirements could result in delisting of securities, leading to decreased trading volume, lower security price, and difficulties in raising capital.
• The temporary limitation on utilizing Form S-3 without an SEC waiver will materially and adversely impact the company's ability to raise capital and execute its business plan, potentially requiring private placements with less favorable terms or delays.
• The company's cash and cash equivalents are concentrated in one financial institution, with approximately $5.0 million in excess of FDIC insurance limits as of September 30, 2025, posing a credit risk.
• Uncertainty exists regarding the timing and amount of future revenue from development-stage biotherapeutic programs and approved therapies.
• Future capital requirements are dependent on numerous factors, including clinical trial progress, regulatory approvals, commercialization costs, and intellectual property defense, making it difficult to estimate funding needs accurately.

Future Outlook

Management expects operating losses and negative cash flows to continue for at least the next several years, with increasing costs as clinical trials and development activities advance. The company anticipates needing additional funding beyond the second quarter of 2026 and plans to raise capital through debt, equity, or non-dilutive arrangements. They expect to complete submission of CardiAMP HF data and request an FDA meeting in the fourth quarter of 2025 to discuss approvability. Phase 2 development for CardiALLO is anticipated to advance in both the United States and Japan in approximately one year, with potential conditional approval in Japan after completion.

Management Comments

• Management expects operating losses and negative cash flows to continue through at least the next several years.
• Management believes our cash and cash equivalents of approximately $5.3 million as of September 30, 2025 are not sufficient to fund our planned expenditures and meet our obligations beyond the second quarter of 2026.
• We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations.
• While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within their control and cannot be assessed as being probable of occurring.
• We intend to prepare the primary results of this cohort [CardiAMP CMI roll-in] for publication and presentation.
• We intend to fund development through nondilutive grants and partnering.
• We intend to submit for approval of the Helix Transendocardial Delivery System (Helix) to FDA as a DeNovo 510(k) application based on its safety and performance in twelve cell and gene therapy clinical studies.
• We are actively transitioning all procedures using our Helix transendocardial delivery system to our new FDA cleared Morph DNA platform.
• We believe it [Morph DNA] presents significant advantages for procedures in the left ventricle of the heart, such as cell and gene therapy and ablation of ventricular tachyarrhythmia.
• Heart3D is expected to be sold initially as a research tool with support services for partners in preclinical studies and subsequently approved for standard clinical practice.

Industry Context

BioCardia operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, focusing on cardiovascular and pulmonary cell therapies. The company's strategy of developing both autologous and allogeneic cell therapies, coupled with proprietary delivery systems like Helix and Morph DNA, positions it within the growing field of regenerative medicine and targeted biotherapeutic delivery. The pursuit of FDA Breakthrough designation and engagement with Japan's PMDA highlights efforts to accelerate market access in key global regions. The reliance on equity financing and the 'going concern' warning are common challenges for clinical-stage biotechs prior to commercialization and significant revenue generation.

Comparison to Industry Standards

• The CardiAMP HF trial's statistically significant composite endpoint in patients with elevated NTproBNP suggests a targeted efficacy that could differentiate it in the heart failure treatment landscape, where many therapies offer incremental benefits.
• The Helix system's reported safety standard with over 4,000 intramyocardial deliveries and superior therapeutic agent retention compared to other catheter and surgical delivery approaches sets a high benchmark for delivery platforms in cell and gene therapy.
• The company's repeated reliance on dilutive equity financing, including ATM offerings and private placements with warrants, is a common funding mechanism for clinical-stage biotech companies but also indicates a lack of significant non-dilutive revenue streams or partnerships to date, which is a challenge for many smaller players in the industry.
• The "going concern" warning is a standard disclosure for companies with significant research and development expenses and no commercialized products, reflecting the inherent financial risks in drug development, but it also signals a critical need for near-term capital that could be more challenging given the Form S-3 limitation.

Corporate Governance

Related Party Transactions

• Certain directors and executive officers purchased an aggregate of 211,000 shares of Common Stock and accompanying Common Warrants in the September 2024 Registered Offering.
• Certain members of the board of directors and executive officers participated in the April 2025 Offering, purchasing shares of common stock and warrants.
• Certain members of the board of directors and executive officers participated in the June 2025 Offering, purchasing shares of common stock and warrants.
• Certain directors and executive officers purchased an aggregate of 734,400 shares of common Stock and accompanying September 2025 Warrants in the September 2025 Offering, representing gross proceeds of $918,000.

Stakeholder Impact

• Shareholders: Significant dilution from multiple equity offerings, and potential for further dilution due to ongoing capital needs. The "going concern" warning and Form S-3 limitation pose substantial risks to investment value.
• Employees: Continued operating losses and the "going concern" warning could create uncertainty regarding job security and future compensation.
• Customers/Partners: Clinical trial progress and FDA/PMDA consultations could build confidence, but financial instability might raise concerns about long-term viability and ability to deliver on partnerships.
• Creditors: The "going concern" warning indicates increased risk for existing and potential creditors.

Next Steps

• Raise additional capital through debt, equity, or non-dilutive arrangements to fund operations beyond Q2 2026.
• Seek an SEC waiver to regain Form S-3 eligibility to facilitate efficient capital raising.
• Complete submission of CardiAMP HF data and request a meeting with the FDA in Q4 2025 to discuss approvability for ischemic heart failure.
• Conduct a formal in-person clinical consultation with Japan's PMDA near the end of 2025 for potential CardiAMP system approval submission in Japan.
• Continue patient randomization and onboarding additional centers for the CardiAMP HF II Phase 3 trial.
• Prepare primary results of the CardiAMP CMI open-label roll-in cohort for publication and presentation.
• Advance Phase 2 development for CardiALLO allogeneic MSC in both the United States and Japan, anticipated to enroll in approximately one year.
• Pursue conditional approval in Japan for CardiALLO after completion of the Phase 2 study, followed by a post-marketing study.
• Submit for FDA DeNovo 510(k) approval for the Helix Transendocardial Delivery System.
• Actively transition all Helix procedures to the new FDA cleared Morph DNA platform.
• Initially sell the Heart3D system as a research tool with support services for partners in preclinical studies, then seek approval for standard clinical practice.

Key Dates

Recommendation

Despite promising clinical trial data for its cell therapies and delivery systems, BioCardia faces severe financial distress, explicitly stating a 'substantial doubt about its ability to continue as a going concern' beyond Q2 2026. The company has an accumulated deficit of $166.4 million and relies heavily on dilutive equity financing, which has already led to a significant increase in shares outstanding. Furthermore, a regulatory compliance issue has temporarily limited its ability to use Form S-3, severely hindering its capacity to raise capital efficiently. This combination of critical liquidity issues, ongoing losses, and significant financing challenges creates an extremely high-risk profile, making the stock a strong sell for investors.

Keywords

BioCardia, BCDA, SEC Filing, 10-Q, Q3 2025, Cell Therapy, CardiAMP, Heart Failure, HFrEF, Chronic Myocardial Ischemia, Refractory Angina, CardiALLO, Mesenchymal Stem Cell, MSC, ARDS, Helix Delivery System, Morph DNA, Heart3D, Clinical Trials, FDA Breakthrough, PMDA Japan, Going Concern, Capital Raise, Equity Financing, Warrants, Nasdaq Listing, Form S-3, Biotechnology, Cardiovascular Disease, Pulmonary Disease